文献速递基础与转化研究临床试验与 GCP

HER2特异性CAR T细胞局部输注治疗儿童及年轻成人复发或难治性中枢神经系统肿瘤的 interim 分析

Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.
PubMed 文献 · Nat Med · 2021-07-12

该研究在髓母细胞瘤原位异种移植模型中证实中等长度CAR间隔区可增强HER2特异性CAR T细胞疗效,并转化为BrainChild-01(NCT03500991)1期临床试验。初步3例患者经CNS导管重复局部输注未出现剂量限制性毒性,脑脊液中CXCL10和CCL2升高提示局部免疫激活,支持该疗法的可行性与耐受性。

要点

  • 中等长度CAR间隔区增强HER2 CAR T细胞在髓母细胞瘤模型中的疗效
  • 3例患者重复CNS局部输注未出现剂量限制性毒性
  • 脑脊液CXCL10和CCL2升高提示局部免疫激活

核心结论

  • 重复CNS局部输注HER2特异性CAR T细胞在儿童及年轻成人复发/难治性CNS肿瘤中可行且可能耐受良好,并能激活局部免疫反应。

研究设计与样本

  • 临床前研究:在髓母细胞瘤原位异种移植模型中比较CAR间隔区工程化改造的疗效。
  • 临床试验:BrainChild-01(NCT03500991),西雅图儿童医院正在进行的1期试验,评估重复局部输注HER2特异性CAR T细胞。
  • 主要目标为可行性、安全性和耐受性;次要目标包括CAR T细胞分布和疾病反应。

主要发现

  • 中等长度CAR间隔区增强HER2特异性CAR T细胞在髓母细胞瘤原位异种移植模型中的治疗 efficacy。
  • 初始3例患者未出现剂量限制性毒性。
  • 患者表现出临床及实验室证据的局部CNS免疫激活,包括脑脊液中CXCL10和CCL2高浓度。

关键数值与推荐

  • 患者通过CNS导管接受输注,途径为肿瘤腔或脑室系统,在门诊环境中进行。
  • 初始3例患者未报告剂量限制性毒性。

临床怎么用

  • 支持在儿童及年轻成人复发/难治性CNS肿瘤中开展重复CNS局部输注HER2特异性CAR T细胞的进一步研究。

局限性

  • 为interim分析,样本量有限(初始3例患者)。
  • 需要更多患者和更长期随访评估疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Locoregional delivery of chimeric antigen receptor (CAR) T cells has resulted in objective responses in adults with glioblastoma, but the feasibility and tolerability of this approach is yet to be evaluated for pediatric central nervous system (CNS) tumors. Here we show that engineering of a medium-length CAR spacer enhances the therapeutic efficacy of human erb-b2 receptor tyrosine kinase 2 (HER2)-specific CAR T cells in an orthotopic xenograft medulloblastoma model. We translated these findings into BrainChild-01 ( NCT03500991 ), an ongoing phase 1 clinical trial at Seattle Children's evaluating repetitive locoregional dosing of these HER2-specific CAR T cells to children and young adults with recurrent/refractory CNS tumors, including diffuse midline glioma. Primary objectives are assessing feasibility, safety and tolerability; secondary objectives include assessing CAR T cell distribution and disease response. In the outpatient setting, patients receive infusions via CNS catheter into either the tumor cavity or the ventricular system. The initial three patients experienced no dose-limiting toxicity and exhibited clinical, as well as correlative laboratory, evidence of local CNS immune activation, including high concentrations of CXCL10 and CCL2 in the cerebrospinal fluid. This interim report supports the feasibility of generating HER2-specific CAR T cells for repeated dosing regimens and suggests that their repeated intra-CNS delivery might be well tolerated and activate a localized immune response in pediatric and young adult patients.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Vitanza NA, Johnson AJ, Wilson AL, et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med. 2021. PMID: 34253928. doi:10.1038/s41591-021-01404-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。